DESCRIPTION

Insulin degludec is a long-acting basal human insulin analog for subcutaneous injection produced by a process that includes expression of recombinant DNA in

Saccharomyces cerevisiae followed by chemical modification. Insulin degludec differs from human insulin in that the amino acid threonine in position B30 has been

omitted and a side chain consisting of glutamic acid and a

C16 fatty acid has been attached (chemical name:

LysB29(Nε hexadecandioyl γ Glu) des(B30) human insulin). Insulin degludec has a molecular formula of C274H411N65O81S6 and a molecular weight of 6.104 kDa. It has the following structure:

INSULIN DEGLUDEC INJECTION (insulin degludec) injection is a sterile, aqueous, clear, and colorless solution available as 100 units/mL (U 100) or 200 units/mL (U 200) for subcutaneous use. For the 100 units/mL solution, each mL contains 100 units of insulin degludec and glycerin (19.6 mg), metacresol (1.72 mg), phenol (1.5 mg), zinc (32.7 mcg), and Water for Injection, USP. For the 200 units/mL solution, each mL contains 200 units of insulin degludec and glycerin (19.6 mg), metacresol (1.72 mg), phenol (1.5 mg), zinc (71.9 mcg), and Water for Injection, USP. INSULIN DEGLUDEC INJECTION has a pH of approximately 7.6. Hydrochloric acid or sodium hydroxide may be added to adjust pH.

 

Mechanism of Action

The primary activity of insulin, including INSULIN DEGLUDEC INJECTION, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis. INSULIN DEGLUDEC INJECTION forms multi hexamers when injected into the subcutaneous tissue resulting in a subcutaneous insulin degludec depot. The protracted time action profile of INSULIN DEGLUDEC INJECTION is predominantly due to delayed absorption of insulin degludec from the subcutaneous tissue to the systemic circulation and to a lesser extent due to binding of insulin degludec to circulating albumin.

Pharmacodynamics

The glucose lowering effect of INSULIN DEGLUDEC after 8 days of once daily dosing was measured in a euglycemic glucose clamp study enrolling 21 patients with type 1 diabetes. Figure 2 shows the pharmacodynamic effect of INSULIN DEGLUDEC over time following 8 once daily subcutaneous injections of 0.4 U/kg of INSULIN DEGLUDEC in patients with type 1 diabetes.

Name: Insulin Degludec Injection

Insulin degludec is a prescription medicine used to treat the symptoms of Type 1 or 2 Diabetes Mellitus. Tresiba may be used alone or with other medications.

Dosage: Injection

Specification: 3ml: 300units

Indications

Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Company Advantage

Hangzhou Jiuyuan is a top-biotech joint venture specializing in the research, development, manufacture and marketing of pharmaceuticals based on gene engineering and biochemical technology since 1993. It has gene engineering workshops, injection workshops, pharmaceutical API workshops and other sections including quality management department, warehouse, engineering department etc., all of which are built according to GMP requirements. Jiuyuan is equipped with advanced production and analysis instruments like chromatography system, HPLC and capillary electrophoresis.We offer high quality products and comprehensive sales services, please contact us.

Company Honor

National New High-tech Enterprise

Key New High-tech Enterprise of National Torch Plan

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center

Zhejiang Provincial Enterprise Technology Center

Zhejiang Famous Trademark

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

FAQ

Q: Are you trading company or manufacturer?

A: We are professional manufacturer specialized in the research, development, manufacture and marketing of pharmaceuticals based on gene engineering and biochemical technology since 1993.

And we trade our products with our clients directly.

Q: How many different types of products your company manufactures?

A: Now we have 36 products including pipeline products. All the pharmaceutical manufacturing activities are carried as per GMP requirements. The day to day licensing and regulatory activities are controlled by SFDA.

Q: When can I get the price?

A: Usually we quote within 8 hours after we get your inquiry.

Q: What's your MOQ?

A: If we have the products in stock, it will be no MOQ. If we need to produce, we can discuss the MOQ according to customer's exact situation.

http://www.jiuyuangene.net/